CompletedNot Applicable

Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis

Japan2,157 participantsStarted 2011-01-01

Plain-language summary

To investigate the efficacy and safety of PARIET twice daily (b.i.d.) in patients with Proton Pump Inhibitor-resistant reflux esophagitis

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓Proton pump inhibitor-resistant reflux esophagitis. (Patients who have mucosal breaks (erosions, ulcers) on endoscopy)

Number of subjects with improvement based on health related Quality of Life (QOL) questionnaire

Timeframe: Check at predose, 4, 8, 16 and 32 weeks

NCT IDNCT01321567

SponsorEisai Co., Ltd.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2013-03-01